Anlotinib (AL3818)

Anlotinib (AL3818) is a novel, orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI) primarily developed for the treatment of various solid tumors (Shen et al., 2018). It is not a biological target itself but rather a therapeutic agent that inhibits a broad spectrum of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and the stem cell factor receptor (c-Kit) (Sun et al., 2016; Xie et al., 2018). By blocking these critical signaling pathways, anlotinib effectively suppresses tumor angiogenesis, cell proliferation, and metastasis (Shen et al., 2018). It has demonstrated significant clinical efficacy in treating advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, and medullary thyroid carcinoma, particularly in patients who have failed prior lines of therapy (Han et al., 2018; Chi et al., 2018). Common adverse effects associated with its use include hypertension and hand-foot skin syndrome, which are typical of its class of anti-angiogenic agents (Shen et al., 2018). The drug was developed by Chia Tai Tianqing Pharmaceutical Group and has been approved for several indications in China (Xie et al., 2018).

Other names

AL3818Anlotinib dihydrochlorideFocusV

Multi-target tyrosine kinase inhibition, specifically targeting VEGFR1/2/3, FGFR1-4, PDGFR-α/β, and c-Kit.